Medtronic Launches FDA-Cleared Spinal Tumor Ablation Tech

FierceMedical Devices reported that Medtronic (NYSE:MDT) has launched a radiofrequency (RF) ablation tech in the US after it received 510(k) clearance from the FDA in November. Medtronic acquired the OsteoCool RF Ablation System from Baylis Medical in December.
According to the article:

The OsteoCool device uses high-frequency energy to ablate metastatic spinal tumors in order to reduce patient pain. Medtronic expects that it could be useful in a procedure to treat cancer-related microfractures with its Kyphon Xpede Bone Cement that also received an expanded indication from the FDA in November.

Julie Foster, GM and VP of the Pain Therapies business in Medtronic’s Neuromodulation division commented:

The OsteoCool System expands our Pain Therapies portfolio. Our customers treat patients with Kyphon Balloon Kyphoplasty who also have painful spinal metastases. The OsteoCool system gives physicians a way to treat that pain in a single procedure with a familiar, minimally invasive technique.

Click here to view the full press release.